New strategies to direct therapeutic targeting of PML to treat cancers

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Wolyniec, Kamil ^a,b   Carney, Dennis A ^a,b   Haupt, Sue ^a,b   Haupt, Ygal ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

BMK1; CK2; E6AP; KLHL20; PML; Small molecule inhibitors; Targeted anti cancer therapy; Tumour suppression

Indexed keywords

CASEIN KINASE II; CD34 ANTIGEN; CULLIN; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; INTERFERON; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEVONEDISTAT; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN INHIBITOR; STAT PROTEIN; TRICHOSTATIN A; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; XMD 8 92;

ACETYLATION; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; GAIN OF FUNCTION MUTATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; ISOMERIZATION; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION;

EID: 84891048254     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00124     Document Type: Review

References (93)

1. Acosta, J. C., and Gil, J. (2012). Senescence: a new weapon for cancer therapy. Trends Cell Biol. 22, 211-219.
2. Alsheich-Bartok, O., Haupt, S., Alkalay-Snir, I., Saito, S., Appella, E., and Haupt, Y. (2008). PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene 27, 3653-3661.
3. Bernardi, R., and Pandolfi, P. P. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8, 1006-1016.
4. Bernardi, R., Scaglioni, P. P., Bergmann, S., Horn, H. F., Vousden, K. H., and Pandolfi, P. P. (2004). PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 6, 665-672.
5. Boe, S. O., and Simonsen, A. (2010). Autophagic degradation of an oncoprotein. Autophagy 6, 964-965.
6. Borrow, J., Goddard, A. D., Sheer, D., and Solomon, E. (1990). Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249, 1577-1580.
7. Campagna, M., Herranz, D., Garcia, M. A., Marcos-Villar, L., Gonzalez-Santamaria, J., Gallego, P., et al. (2011). SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ. 18, 72-79.
8. Carracedo, A., Ito, K., and Pandolfi, P. P. (2011). The nuclear bodies inside out: PML conquers the cytoplasm. Curr. Opin. Cell Biol. 23, 360-366.
9. Carracedo, A., Weiss, D., Leliaert, A. K., Bhasin, M., de Boer, V. C., Laurent, G., et al. (2012). A metabolic prosurvival role for PML in breast cancer. J. Clin. Invest. 122, 3088-3100.
10. Chelbi-Alix, M. K., Pelicano, L., Quignon, F., Koken, M. H., Venturini, L., Stadler, M., et al. (1995). Induction of the PML protein by interferons in normal and APL cells. Leukemia 9, 2027-2033.
11. Chen, G. Q., Shi, X. G., Tang, W., Xiong, S. M., Zhu, J., Cai, X., et al. (1997). Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89, 3345-3353.
12. Chen, R., Yang, Q., and Lee, J. D. (2012a). BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3beta signaling pathway. Cancer Res. 72, 1579-1587.
13. Chen, R. H., Lee, Y. R., and Yuan, W. C. (2012b). The role of PML ubiquitination in human malignancies. J. Biomed. Sci. 19, 81.
14. Chiantore, M. V., Vannucchi, S., Accardi, R., Tommasino, M., Percario, Z. A., Vaccari, G., et al. (2012). Interferon-beta induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS ONE 7:e36909. doi:10.1371/journal.pone.0036909
15. Daniel, M. T., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., et al. (1993). PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82, 1858-1867.
16. de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G., et al. (2004). PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13, 523-535.
17. de Thé, H., and Chen, Z. (2010). Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 10, 775-783.
18. de Thé, H., Chomienne, C., Lanotte, M., Degos, L., and Dejean, A. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347, 558-561.
19. de Thé, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., and Dejean, A. (1991). The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675-684.
20. Dellaire, G., and Bazett-Jones, D. P. (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26, 963-977.
21. Der, S. D., Zhou, A., Williams, B. R., and Silverman, R. H. (1998). Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 95, 15623-15628.
22. Fanelli, M., Fantozzi, A., de Luca, P., Caprodossi, S., Matsuzawa, S., Lazar, M. A., et al. (2004). The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J. Biol. Chem. 279, 5374-5379.
23. Ferbeyre, G. (2002). PML a target of translocations in APL is a regulator of cellular senescence. Leukemia 16, 1918-1926.
24. Geoffroy, M. C., and Chelbi-Alix, M. K. (2011). Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31, 145-158.
25. Ghavamzadeh, A., Alimoghaddam, K., Rostami, S., Ghaffari, S. H., Jahani, M., Iravani, M., et al. (2011). Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J. Clin. Oncol. 29, 2753-2757.
26. Guan, D., Factor, D., Liu, Y., Wang, Z., and Kao, H. Y. (2012). The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein. Oncogene. doi:10.1038/onc.2012.406. [Epub ahead of print].
27. Gurrieri, C., Capodieci, P., Bernardi, R., Scaglioni, P. P., Nafa, K., Rush, L. J., et al. (2004a). Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96, 269-279.
28. Gurrieri, C., Nafa, K., Merghoub, T., Bernardi, R., Capodieci, P., Biondi, A., et al. (2004b). Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 103, 2358-2362.
29. Haupt, S., DI Agostino, S., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., et al. (2009). Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res. 69, 4818-4826.
30. Haupt, S., Mitchell, C., Corneille, V., Shortt, J., Fox, S., Pandolfi, P. P., et al. (2013). Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender dependent manner. Cell Cycle (in press).
31. Hayakawa, F., Abe, A., Kitabayashi, I., Pandolfi, P. P., and Naoe, T. (2008). Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J. Biol. Chem. 283, 24420-24425.
32. Hayakawa, F., and Privalsky, M. L. (2004). Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389-401.
33. Holtz, M., Forman, S. J., and Bhatia, R. (2007). Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 67, 1113-1120.
34. Hope, K. J., Jin, L., and Dick, J. E. (2004). Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738-743.
35. Hu, J., Liu, Y. F., Wu, C. F., Xu, F., Shen, Z. X., Zhu, Y. M., et al. (2009). Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 106, 3342-3347.
36. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Zhoa, L., et al. (1988). Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572.
37. Hubackova, S., Krejcikova, K., Bartek, J., and Hodny, Z. (2012). Interleukin 6 signaling regulates promyelocytic leukemia protein gene expression in human normal and cancer cells. J. Biol. Chem. 287, 26702-26714.
38. Hubackova, S., Novakova, Z., Krejcikova, K., Kosar, M., Dobrovolna, J., Duskova, P., et al. (2010). Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle 9, 3085-3099.
39. Iland, H. J., Bradstock, K., Supple, S. G., Catalano, A., Collins, M., Hertzberg, M., et al. (2012). All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120, 1570-1580.
40. Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., et al. (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072-1078.
41. Ito, K., Carracedo, A., Weiss, D., Arai, F., Ala, U., Avigan, D. E., et al. (2012). A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18, 1350-1358.
42. Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., LE Bras, M., Duffort, S., et al. (2010). PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18, 88-98.
43. Koken, M. H., Linares-Cruz, G., Quignon, F., Viron, A., Chelbi-Alix, M. K., Sobczak-Thepot, J., et al. (1995). The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10, 1315-1324.
44. Koken, M. H., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., et al. (1994). The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 13, 1073-1083.
45. Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., et al. (2008). Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547-555.
46. Lallemand-Breitenbach, V., Zhu, J., Chen, Z., and de Thé, H. (2012). Curing APL through PML/RARA degradation by As2O3. Trends Mol. Med. 18, 36-42.
47. Lavau, C., Marchio, A., Fagioli, M., Jansen, J., Falini, B., Lebon, P., et al. (1995). The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 11, 871-876.
48. Lee, H. E., Jee, C. D., Kim, M. A., Lee, H. S., Lee, Y. M., Lee, B. L., et al. (2007). Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett. 247, 103-109.
49. Li, L., Wang, J., Ye, R. D., Shi, G., Jin, H., Tang, X., et al. (2008). PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J. Cell. Physiol. 217, 486-493.
50. Lim, J. H., Liu, Y., Reineke, E., and Kao, H. Y. (2011). Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover. J. Biol. Chem. 286, 44403-44411.
51. Louria-Hayon, I., Alsheich-Bartok, O., Levav-Cohen, Y., Silberman, I., Berger, M., Grossman, T., et al. (2009). E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ. 16, 1156-1166.
52. Louria-Hayon, I., Grossman, T., Sionov, R. V., Alsheich, O., Pandolfi, P. P., and Haupt, Y. (2003). The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem. 278, 33134-33141.
53. Mathews, V., George, B., Chendamarai, E., Lakshmi, K. M., Desire, S., Balasubramanian, P., et al. (2010). Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J. Clin. Oncol. 28, 3866-3871.
54. Miller, W. H. Jr., Schipper, H. M., Lee, J. S., Singer, J., and Waxman, S. (2002). Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893-3903.
55. Muller, S., Matunis, M. J., and Dejean, A. (1998a). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17, 61-70.
56. Muller, S., Miller, W. H. Jr., and Dejean, A. (1998b). Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92, 4308-4316.
57. Novakova, Z., Hubackova, S., Kosar, M., Janderova-Rossmeislova, L., Dobrovolna, J., Vasicova, P., et al. (2010). Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 29, 273-284.
58. Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J. A., Outzen, H., et al. (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131-24145.
59. Peche, L. Y., Scolz, M., Ladelfa, M. F., Monte, M., and Schneider, C. (2012). MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ. 19, 926-936.
60. Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., et al. (2010). Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116, 3751-3757.
61. Rabellino, A., Carter, B., Konstantinidou, G., Wu, S. Y., Rimessi, A., Byers, L. A., et al. (2012). The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72, 2275-2284.
62. Ravandi, F., Estey, E., Jones, D., Faderl, S., O'Brien, S., Fiorentino, J., et al. (2009). Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol. 27, 504-510.
63. Rego, E. M., He, L. Z., Warrell, R. P. Jr., Wang, Z. G., and Pandolfi, P. P. (2000). Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. U.S.A. 97, 10173-10178.
64. Rego, E. M., and Pandolfi, P. P. (2001). Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin. Hematol. 38, 54-70.
65. Reineke, E. L., Liu, Y., and Kao, H. Y. (2010). Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J. Biol. Chem. 285, 9485-9492.
66. Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
67. Salomoni, P., Dvorkina, M., and Michod, D. (2012). Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis. 3, e247.
68. Salomoni, P., Ferguson, B. J., Wyllie, A. H., and Rich, T. (2008). New insights into the role of PML in tumour suppression. Cell Res. 18, 622-640.
69. Scaglioni, P. P., Yung, T. M., Cai, L. F., Erdjument-Bromage, H., Kaufman, A. J., Singh, B., et al. (2006). A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126, 269-283.
70. Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., et al. (1998). Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90, 124-133.
71. Shen, T. H., Lin, H. K., Scaglioni, P. P., Yung, T. M., and Pandolfi, P. P. (2006). The mechanisms of PML-nuclear body formation. Mol. Cell 24, 331-339.
72. Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., et al. (2009). An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736.
73. Srinivasan, S., and Nawaz, Z. (2011). E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth. Biochim. Biophys. Acta 1809, 119-127.
74. Stadler, M., Chelbi-Alix, M. K., Koken, M. H., Venturini, L., Lee, C., Saib, A., et al. (1995). Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 11, 2565-2573.
75. Sun, H. D., Ma, L., Hu, X. C., and Zhang, T. D. (1992). Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin. J. Integr. Chin. West. Med. 12, 170-171.
76. Tatham, M. H., Geoffroy, M. C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E. G., et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538-546.
77. Terris, B., Baldin, V., Dubois, S., Degott, C., Flejou, J. F., Henin, D., et al. (1995). PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res. 55, 1590-1597.
78. Trotman, L. C., Alimonti, A., Scaglioni, P. P., Koutcher, J. A., Cordon-Cardo, C., and Pandolfi, P. P. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523-527.
79. Vincenzi, B., Perrone, G., Santini, D., Grosso, F., Silletta, M., Frezza, A., et al. (2010). PML down-regulation in soft tissue sarcomas. J. Cell. Physiol. 224, 644-648.
80. Wang, Z., Cao, L., Kang, R., Yang, M., Liu, L., Zhao, Y., et al. (2011). Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARalpha oncoprotein. Autophagy 7, 401-411.
81. Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., et al. (1994). Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 76, 345-356.
82. Wolyniec, K., Chan, A. L., Haupt, S., and Haupt, Y. (2012a). Restoring PML tumor suppression to combat cancer. Cell Cycle 11, 3705-3706.
83. Wolyniec, K., Shortt, J., de Stanchina, E., Levav-Cohen, Y., Alsheich-Bartok, O., Louria-Hayon, I., et al. (2012b). E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood 120, 822-832.
84. Yamagishi, Y., Shoji, I., Miyagawa, S., Kawakami, T., Katoh, T., Goto, Y., et al. (2011). Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. Chem. Biol. 18, 1562-1570.
85. Yan, W., Zhang, Y., Zhang, J., Liu, S., Cho, S. J., and Chen, X. (2011). Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J. Biol. Chem. 286, 17478-17486.
86. Yang, Q., Deng, X., Lu, B., Cameron, M., Fearns, C., Patricelli, M. P., et al. (2010). Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18, 258-267.
87. Yang, Q., Liao, L., Deng, X., Chen, R., Gray, N. S., Yates, J. R. III, et al. (2012). BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene. doi:10.1038/onc.2012.332. [Epub ahead of print].
88. Yi, J., Gao, F., Shi, G., Li, H., Wang, Z., Shi, X., et al. (2002). The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 7, 209-215.
89. Yi, J., Yang, J., He, R., Gao, F., Sang, H., Tang, X., et al. (2004). Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 64, 108-116.
90. Yuan, W. C., Lee, Y. R., Huang, S. F., Lin, Y. M., Chen, T. Y., Chung, H. C., et al. (2011). A cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 20, 214-228.
91. Zhang, P., Chin, W., Chow, L. T., Chan, A. S., Yim, A. P., Leung, S. F., et al. (2000). Lack of expression for the suppressor PML in human small cell lung carcinoma. Int. J. Cancer 85, 599-605.
92. Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., et al. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240-243.
93. Zhu, J., Chen, Z., Lallemand-Breitenbach, V., and de Thé, H. (2002). How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2, 705-713.